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cost-effective. CONCLUSIONS: While the current practice of recommending DMT 
for any patient with progressive MS results in substantial health gains, these gains
come at a very high drug cost, rendering the incremental cost-effectiveness ratios of 
each of the DMTs far above currently accepted standards.
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OBJECTIVES: Chemotherapy-associated peripheral neuropathy (CAPN) is a painful 
side-effect of chemotherapy. Comprehensive measures of health outcomes, medical
costs, and workloss burden of CAPN in patients with breast, ovarian, head/neck, or
non-small cell lung cancer (NSCLC) have not been quantiﬁ ed. This study assesses the
outcomes and direct and indirect cost burden of CAPN in these four tumor types from 
a third-party payer perspective. METHODS: Data were from an administrative claims
database of privately insured companies covering 1999–2006. Patients with qualifying 
tumors, and claims for chemotherapy and services indicative of peripheral neuropathy 
(PN) within 9-months of chemotherapy were selected. Cases were matched 1:1 to
controls with no PN-related claims based on cancer type, diabetes history, demograph-
ics, and propensity for reporting PN claims during the study period (estimated on
baseline resource use and comorbidities). Direct costs and resource use were calculated 
for a 12-month study period using diagnosis and procedure codes, pharmacy claims,
and provider specialty codes. Indirect costs were obtained for a subset of patients that
had disability and medically related absenteeism data. Comparisons of cost and
resource use between cases and controls used paired t-tests. RESULTS: Among patients
treated for breast, ovarian, head/neck, and NSCLC, 454 were identiﬁ ed who met 
inclusion criteria and had evidence of CAPN. Average direct costs were $17,344 higher
for CAPN cases than non-CAPN controls (p  0.0001). Outpatient costs were the 
highest component for both cases and controls with cases having excess outpatient
costs of $8092 (p  0.001). On average, each CAPN case had 12 more outpatient 
visits than controls (51.3 vs. 39.8 visits; p  0.0001), and spent more days in the hos-
pital (5.6 vs. 3.2 days; p  0.001). Indirect resource use and costs were higher for
cases but not statistically different from controls. CONCLUSIONS: CAPN is associ-
ated with increased direct medical cost and resource use of patients with breast,
ovarian, head/neck, or NSCLC.
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OBJECTIVES: Dementia patients often receive cholinesterase inhibitors and/or 
memantine (CIM) for cognitive symptoms, and antidepressants (AD) for behavioral 
symptoms. Ideally, patient demographics or clinic locations have no effect on care
received. We explored whether patient demographics and/or outpatient referrals to
specialized dementia or mental health clinics inﬂ uenced the likelihood of receiving 
CIM/AD medications. METHODS: Veteran’s Affairs Maryland Health Care System 
(VAMHCS) electronic medical records were used to select a cohort, based on diagnosis 
codes or medications indicating Alzheimer’s or related dementias. Patients aged 60 
and above, with index dates after 1999 were selected. Additional criteria included:
minimum of one year follow up or death within a year of index date. The outcome
(referent) was categorized as: receipt of CIM, receipt of AD, receipt of both CIM/AD 
(receipt of neither medication type). Multivariable multinomial logistic models (MLM)
explored predictors of CIM and AD utilization categories, including age, time in
cohort, race, marital status, and referrals to dementia or mental health clinics.
RESULTS: A cohort of 1359 patients, average age of 78.1 (SD 6.0) years and 22% 
African-Americans, was followed up for an average of 3.1 (SD 1.9) years. Thirty-ﬁ ve
percent had mental health or dementia clinic visits while 18% visited both clinics.
Signiﬁ cant associations were found for receiving both CIM and AD medications versus 
receiving no medication for years in cohort (OR  1.237, p  0.0001), African-Ameri-
can race (OR  0.437, p  0.0001), age (OR  0.966, p  0.0288),) marital status 
(OR  1.492, p  0.0339) and mental health clinic visit (OR  3.386, p  0.0001). 
Dementia clinic visit was associated with CIM only but not receipt of both medications
(OR  1.405, p  0.0996). CONCLUSIONS: In veterans with possible dementia, 
demographic factors and care at dementia/mental health clinics impact the likelihood 
of receiving CIM/AD medications. These found associations need to be further inves-
tigated for their potential impact on patient outcome.
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OBJECTIVES: To estimate the cost-utility of interferon-beta-1b (IFNB-1b) for the
treatment of patients with a clinically isolated syndrome (CIS) suggestive of multiple
sclerosis (MS) using ﬁ ve year BENEFIT clinical trial data. METHODS: We developed 
a Markov model of the epidemiology and treatment of CIS and MS. A hypothetical 
cohort of 1000 patients with incident CIS, with initial health states deﬁ ned by Kurtz-
ke’s Expanded Disability Symptom Scale (EDSS), was speciﬁ ed. The cohort was
assumed to be treated with either IFNB-1b (250 mcg eod) following an initial demye-
linating event suggestive of MS or not treated until conﬁ rmation of Poser-deﬁ ned MS. 
Data from BENEFIT were used to model EDSS transitions and transition from CIS 
to MS. Relapses were estimated from BENEFIT and published natural history data.
Following transition to MS, all patients were assumed to be treated with IFNB-1b
until reaching EDSS 6.5. Direct and indirect medical costs of MS treatment and IFNB-
1b were estimated using published literature and pricing schedules. Patient utilities
were derived from EQ-5D data from BENEFIT, supplemented by published data 
deﬁ ned by EDSS score and relapse occurrence. Mortality was estimated using life 
tables and EDSS data. Costs (2007 AUD) and outcomes were discounted at 5% per 
annum. Sensitivity analyses were performed on all key model parameters. RESULTS:
Use of IFNB-1b was associated with fewer EDSS transitions, longer time to CDMS
diagnosis, and a reduced relapse burden. In the base case (Australian perspective; 25-
year time horizon), the incremental cost utility of IFNB-1b versus no treatment was 
AUD 20,000 (USD 14,000) per quality-adjusted life year (QALY) gained. Findings 
were sensitive to time horizon, IFNB-1b cost and treatment effect, and underlying 
rate of disease progression. CONCLUSIONS: This model shows that IFNB-1b treat-
ment of patients with CIS is cost-effective with a cost per QALY gained within the 
range of many well accepted health care interventions.
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OBJECTIVES: Health information exchange technologies are being implemented
widespread with goals of improving efﬁ ciency and costs of care. The need for timely, 
accurate, and pertinent information is most critical in the emergency department (ED).
This study evaluated the use of a payer-based electronic health record (P-EHR), which 
includes a clinical summary of a patient’s medical and pharmacy claims, in an ED on
length of stay (LOS) and costs of care among a commercially insured population. 
METHODS: A large urban hospital implemented a P-EHR in the ED. The P-EHR 
was evaluated using administrative claims and supplemental hospital data. Encounters
with P-EHR use were identiﬁ ed from claims between September 1, 2005 and February 
17, 2006. Accounting for seasonal variation, historical comparison encounters were
identiﬁ ed from November 1, 2004 to March, 31, 2005. Outcomes included ED LOS 
and cost for the ED encounter. Control variables included age, gender, pre-encounter
six month health care utilization and costs, comorbidity burden, plan type, day of 
week (weekend vs weekday), primary diagnosis, triage severity scores, and ED census. 
Analyses used multivariate generalized linear models and non-parametric bootstrap
for standard errors of predictions. RESULTS: A total of 2288 ED encounters were 
analyzed (779 P-EHR/1509 comparison). ED-only P-EHR encounters were discharged 
19 minutes quicker (95%CI:5–33 minutes) as compared to encounters not associated 
with the P-EHR. Among encounters resulting in hospitalization, the P-EHR was 
associated with a 77 minute reduction in LOS (95%CI:28–126 minutes) as compared
to non-P-EHR encounters. The use of the P-EHR was also associated with $1560 
(95% CI:$43–$2910) savings in total plan expenditures for encounters resulting in 
hospitalization. No signiﬁ cant difference in costs was observed among ED-only 
encounters. CONCLUSIONS: This study highlights that a P-EHR can have a meaning-
ful impact on ED throughput and costs. These beneﬁ ts may translate into improvement
in the care provided to patients and their satisfaction.
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OBJECTIVES: To determine the cost savings resulting from speciﬁ c pharmacist inter-
ventions provided to patients with diabetes and their physicians, using a decision-
analysis modeling approach. METHODS: Prospective, cohort study using Lucas
County employees with diabetes enrolled in an employer-sponsored Medication
Therapy Management program in Northwest Ohio. An expert (comprising of clinical 
pharmacists and researchers) opinion guided clinical model pathway was developed to 
identify and map speciﬁ c pharmacist interventions to corresponding responses and
outcomes. Interventions included: 1) alerting physician of patient’s abnormal A1c 
and/or blood sugar proﬁ le; 2) pattern management; 3) instructing on the proper use of 
injectable; 4) glucometer training; 5) advising patients on best way to correct hypogly-
cemic/hyperglycemic episodes. Data was extracted from patient charts and entered into
Microsoft Excel. A 1-year decision-analytic model was constructed using The TreeAge
Pro Suite 2008 to identify the cost-savings per intervention. Probabilities for the inter-
ventions, responses, and outcomes were obtained from real-world data. For example,
